Elona Kogan

Elona is a respected strategic leader in corporate strategy, and M&A having led over $10 billion of merger and acquisition transactions resulting in significant deal premiums and increases in shareholder value and a thought leader in corporate governance.

Elona has significant leadership experience and an operational record of success in product life cycle management from R&D through commercialization, capital raising experience, and therapeutic expertise in oncology, CNS, and cell and gene therapy. Elona's strong financial background and operational expertise are reflected in her election as the Compensation Committee Chair, and Audit Committee member of Cardax, Inc., a public company developing safe, anti-inflammatory medicines. Elona currently serves as the General Counsel of Seer, Inc., a life sciences company focused on enabling exceptional scientific outcomes through unbiased proteomics analysis. In her prior role, Elona served as the General Counsel for Selecta Biosciences, an immune tolerance company, developing novel treatments in gene and cell therapy and rare diseases during which she negotiated several gene therapy collaborations in rare diseases, and helped lead several financing rounds in excess of $75 million. In a prior role, Elona served as the General Counsel and SVP of Government Relations for ARIAD Pharmaceuticals, a rare disease oncology company, during which she led the successful creation of the Government Affairs function, and the strategic sale of the Company for over $5 Billion. Prior to that, Elona held roles of increasing responsibility at King Pharmaceuticals, Inc., acquired by Pfizer, and Avanir Pharmaceuticals, Inc. acquired by Otsuka Pharmaceuticals.

Elona is a founding co-chair of the Women Leaders in Life Sciences conference. Elona is passionate about the arts, educational initiatives improving public school education, and raising the profiles of women and minorities in the legal field and the boardroom.